What is your approach to patients with locally advanced triple negative breast cancer with residual disease at the time of surgery?
Are you using post-neoadjuvant Xeloda based on preliminary data from the CREATE-X trial? Does BRCA mutation influence your decision?
Community PollStarted
What is your approach to patients with locally advanced triple negative breast cancer with residual disease at the time of surgery?
50 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Yale School of Medicine
Answered on
These patients remain at very high risk for metastatic recurrence and therefore should receive adjuvant chemotherapy with capecitabine as standard of care, radiation therapy, and considered for participation in the following adjuvant clinical trials: (1) SWOG S1418 (pembrolizumab versus observation)...
Join for free or sign in to see the full answer